The global AI in drug discovery market was valued at USD 3.00 billion in 2022 and is expected to expand from USD 3.54 billion in 2023 to USD 7.94 billion by 2030, registering a CAGR of 12.2% during the forecast period.

The integration of Artificial Intelligence (AI) in drug discovery is revolutionizing the pharmaceutical industry. AI is significantly reducing the time and cost associated with drug development by predicting drug interactions, identifying potential candidates, and optimizing clinical trials. This article explores the key developments, market drivers, competitive landscape, and future growth prospects of the AI-driven drug discovery market.

Request a Free Sample PDF Brochure of Artificial Intelligence in Drug Discovery Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/105354

Top Companies in the Market

• Microsoft (U.S.)
• Schrödinger, Inc. (U.S.)
• Cresset (U.K.)
• IBM (U.S.)
• Atomwise Inc. (U.S.)
• Insilico Medicine (U.S.)
• Exscientia (U.K.)
• BenevolentAI (U.K.)
• Aria Pharmaceuticals, Inc. (U.S.)
• Integral BioSciences (U.S.)
• Alphabet Inc. (U.S.)

Key Industry Development

November 2022: Cyclica secured a USD 1.8 million grant from the Bill & Melinda Gates Foundation to leverage its AI-enabled drug discovery platform. This investment aims to discover new non-hormonal contraceptives by targeting multiple low-data biological markers.